Report of a 6-month-old Asian infant with early infantile epileptic encephalopathy whose seizures were eliminated by cannabidiol.
We observed that cannabidiol supplements were highly effective in treating an infant boy with drug-resistant early infantile epileptic encephalopathy, eliminating his intractable tonic seizures. The infant began suffering clusters of brief tonic seizures from birth at 39 weeks gestation. EEG showed burst-suppression and seizures could not be controlled by trials of phenobarbital, zonisamide, vitamin B6, clobazam, levetiracetam, topiramate, phenytoin, valproate, high-dose phenobarbital, and ACTH therapy. The boy was discharged from hospital at 130 days of age still averaging tonic seizures 20-30 times per day. We started him on a cannabidiol supplement on day 207, increasing the dosage to 18 mg/kg/d on day 219. His seizures reduced in frequency and completely disappeared by day 234. These effects were maintained, with improved EEG background, even after his other medications were discontinued. Cannabidiol’s effectiveness in treating drug-resistant epilepsy has been confirmed in large-scale clinical trials in Europe and the United States; however, no such trials have been run in Asia. In addition, no reports to date have documented its efficacy in an infant as young as six months of age. This important case suggests that high-dose artisanal cannabidiol may effectively treat drug-resistant epilepsy in patients without access to pharmaceutical-grade CBD.
Keywords: ACTH, adrenocorticotropin hormone; Br, bromide; CBD, cannabidiol; CLB, clobazam; Cannabidiol; EEG, electroencephalogram; EIEE, early infantile epileptic encephalopathy; Early infantile epileptic encephalopathy; Epilepsy; LEV, levetiracetam; LTG, lamotrigine; Medical marijuana; PB, phenobarbital; PHT, phenytoin; THC, tetrahydrocannabidiol; TPM, topiramate; VPA, valproic acid; ZNS, zonisamide.
© 2020 The Authors.
Conflict of interest statement
Authors YM, IT, HY have no conflict of interest. EM is a member of Greenwich Pharmaceutical Speakers Bureau Program. This report is not a funded research.
- EPIDIOLEX (cannabidiol) oral solution [Internet]. Washington DC:FDA [cited 2019 Feb 15] Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210365lbl.pdf
- Devinsky O., Cross J.H., Laux L., Marsh E., Miller I., Nabbout R. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376:2011–2020. – PubMed
- Devinsky O., Patel A.D., Cross J.H., Villaneuva V., Wirrell E.C., Privitera M. Effect of cannabidiol on drop seizures in the Lennox–Gastaut syndrome. N Engl J Med. 2018;378:1888–1897. – PubMed
- Laux L.C., Bebin E.M., Checketts D., Chez M., Flamini R., Marsh E.D. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox–Gastaut syndrome or Dravet syndrome: expanded access program results. Epilepsy Res. 2019;154:13–20. – PubMed
L’article Report of a 6-month-old Asian infant with early infantile epileptic encephalopathy whose seizures were eliminated by cannabidiol. est apparu en premier sur Cannabis Belgique.